PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

Abstract

PARP inhibitors are active in tumors with defects in DNA homologous recombination (HR) due to BRCA1/2 mutations. The phosphoinositide 3-kinase (PI3K) signaling pathway preserves HR steady state. We hypothesized that in BRCA-proficient triple-negative breast cancer (TNBC), PI3K inhibition would result in HR impairment and subsequent sensitization to PARP inhibitors. We show in TNBC cells that PI3K inhibition leads to DNA damage, downregulation of BRCA1/2, gain in poly-ADP-ribosylation, and subsequent sensitization to PARP inhibition. In TNBC patient–derived primary tumor xenografts, dual PI3K and PARP inhibition with BKM120 and olaparib reduced the growth of tumors displaying BRCA1/2 downregulation following PI3K inhibition. PI3K-mediated BRCA downregulation was accompanied by extracellular signal–regulated kinase (ERK) phosphorylation. Overexpression of an active form of MEK1 resulted in ERK activation and downregulation of BRCA1, whereas the MEK inhibitor AZD6244 increased BRCA1/2 expression and reversed the effects of MEK1. We subsequently identified that the ETS1 transcription factor was involved in the ERK-dependent BRCA1/2 downregulation and that knockdown of ETS1 led to increased BRCA1/2 expression, limiting the sensitivity to combined BKM120 and olaparib in 3-dimensional culture. SIGNIFICANCE Treatment options are limited for patients with TNBCs. PARP inhibitors have clinical activity restricted to a small subgroup of patients with BRCA mutations. Here, we show that PI3K blockade results in HR impairment and sensitization to PARP inhibition in TNBCs without BRCA mutations, providing a rationale to combine PI3K and PARP inhibitors in this indication. Our findings could greatly expand the number of patients with breast cancer that would benefit from therapy with PARP inhibitors. On the basis of our findings, a clinical trial with BKM120 and olaparib is being initiated in patients with TNBCs.

Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition

“…This activation also was seen with GDC-0941 alone, albeit to a lesser extent. Recent work from breast cancer models similarly showed that PI3Kα siRNA or the pan-class I-selective NVP-BKM120 increased polyADP ribosylation, pSer139 H2AX, pSer2056 PRKDC, and pSer1981 ATM (35,36). The authors noted the absence of Rad51 foci after PI3Kα inhibition or knockdown and speculated that PRKDC activation may represent a feedback response (36).…”

Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers

“…Although some 'kinase pathways' like the akt/mTOR pathway seems to be involved as well, notably, this pathway acts in concert with tumour suppressors involved in DNA damage response as well as proteins coded for by genes involved in inherited cancer risk syndromes (such as PTEN and TP53). 283,284 Notably, there are cross talks between components of these pathways, and it is likely that different pathways are of variable importance in different tissue compartments. Conceptually, this parallels what we observe for germline mutations and tissue-specific cancer forms.…”

New Strategies in Ovarian Cancer: Translating the Molecular Complexity of Ovarian Cancer into Treatment Advances

“…Other novel combinations in clinical testing include PARPis and PI3K inhibitors; preclinical results combining olaparib and the PI3K inhibitor BKM120 demonstrated synergy (54,55). A phase I study combining these two agents has demonstrated anticancer activity of the combination in patients with recurrent HGSC or triple-negative breast cancer (56).…”